Health
OXGENE launches a scalable, plasmid-free manufacturing system for AAV – News-Medical.net
OXGENE™, a biotechnology company designing and developing scalable gene therapy technologies, has today announced the launch of its scalable, plasmid-free manufacturing system for AAV.
OXGENE™, a biotechnology company designing and developing scalable gene therapy technologies, has today announced the launch of its scalable, plasmid-free manufacturing system for AAV. OXGENE’s new TESSA™ technology addresses industry-wide challenges associated with robust and reproducible AAV manufacture at scale. These include high cost of goods, and low packaging efficiency. TESSA aims to deliver a paradigm shift in scalable AAV manufacture.
Adeno-associated virus, or AAV, is a popular choic…
-
Noosa News18 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
General16 hours agoCrowe toasts talkback titan for platforming ‘voiceless’
-
General11 hours agoPerth man charged after investigation into organised crime and tobacco store attacks
-
Business19 hours agoSolid superannuation gains continue to roll in